Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Thibault Veyron: Optimizing Bivalirudin Treatment in HIT
Nov 21, 2026, 12:49

Thibault Veyron: Optimizing Bivalirudin Treatment in HIT

Thibault Veyron, Medical Doctoral Researcher at CHUV – Lausanne University Hospital, shared a post on LinkedIn:

“A patient’s platelets are dropping. The drug meant to protect them is now the threat.

That’s heparin-induced thrombocytopenia (HIT). One of the main ways to treat it is bivalirudin, a drug that is hard to manage and dosed by guidelines that rarely match what happens at the bedside.

For the past two years, that gap has been the subject of my MD thesis at CHUV: looking at how we actually manage bivalirudin in HIT, and how the guidelines could be revised to better reflect real-world practice.

On Thursday, November 19, I presented this work at the Swiss Oncology & Hematology Congress (SOHC 2026). Five minutes, one poster, and a lot of case files behind it.

None of it would have happened without the Hematology Department at CHUV. Thank you for your guidance, your patience and your time.

Next steps: finishing the manuscript and getting it published.”

Thibault Veyron: Optimizing Bivalirudin Treatment in HIT

Stay updated with Hemostatis Today.